Managing DME When Anti-VEGF Response Is Limited
Retina Minute: Drs. Kuppermann and Singer discuss week-12 findings from the ERLYDEX trial in anti-VEGF suboptimal responders
Clinical Scorecard: Managing DME When Anti-VEGF Response Is Limited
At a Glance
| Category | Detail |
|---|
| Condition | Diabetic Macular Edema (DME) |
| Key Mechanisms | Limited response to anti-VEGF therapy leading to consideration of dexamethasone implant. |
| Target Population | Patients with DME showing suboptimal response to anti-VEGF treatment. |
| Care Setting | Ophthalmology clinics. |
Key Highlights
- 25-33% of DME patients show suboptimal response to anti-VEGF.
- Switching to dexamethasone implant (DEX-I) can improve vision by approximately 8 letters.
- 50% of patients switched to DEX-I gained 10 letters compared to 6% on anti-VEGF.
- No patients on DEX-I lost 10 or more letters at week 12.
- OCT monitoring is essential for assessing treatment response.
Guideline-Based Recommendations
Diagnosis
- Define suboptimal response as less than 5 letters gained and less than 20% CST improvement on anti-VEGF.
Management
- Consider switching to DEX-I after 3 injections of anti-VEGF if suboptimal response is observed.
Monitoring & Follow-up
- Perform OCT at every visit to track CST and macular edema.
Risks
- Potential for vision loss if anti-VEGF therapy is continued without response.
Patient & Prescribing Data
Patients with DME and inadequate response to anti-VEGF therapy.
Switching to DEX-I may lead to improved visual acuity and reduced CST.
Clinical Best Practices
- Switch to dexamethasone implant after determining suboptimal response to anti-VEGF.
- Monitor visual acuity and CST regularly to guide treatment decisions.
References
